Precision Gene Editing Conquers β-Thalassemia in Latest Clinical Breakthrough

This advancement marks a significant shift from the first CRISPR-based therapies by introducing a more refined system with higher accuracy and fewer off-target effects. By successfully targeting β-Thalassemia, researchers are moving closer to universal, safe genomic corrections for inherited blood disorders, signaling a new era of precision medicine.